UBT251 Guide
A GLP-1/GIP/Glucagon Triple Agonist Licensed by Novo Nordisk
UBT251 is a once-weekly triple agonist that hits the same three receptors as Eli Lilly's retatrutide — GLP-1, GIP, and glucagon. Originated by United Biotechnology and licensed by Novo Nordisk outside China, it delivered up to 19.7% weight loss at 24 weeks in Phase 2. Here's where it stands.
What Is UBT251?
UBT251 is an investigational once-weekly injectable triple agonist that activates the GLP-1, GIP, and glucagon receptors simultaneously. That is the same three-receptor "triple G" strategy as retatrutide, the highest-efficacy obesity drug in late-stage development. UBT251 originated with United Biotechnology, and in March 2025 Novo Nordisk licensed rights outside mainland China, Hong Kong, Macau, and Taiwan.
The triple-agonist rationale is to combine the appetite suppression of GLP-1, the metabolic effects of GIP, and the energy-expenditure and fat-burning effects of glucagon — potentially exceeding what dual agonists like tirzepatide achieve.
UBT251 is investigational and not FDA-approved. It is being developed across markets with different sponsors for different regions; broad global data is still years out. It is not available by prescription, and no legitimate retail source exists.
Phase 2 Results
How UBT251 Works
Development Timeline
Guide FAQs
UBT251 is an investigational once-weekly GLP-1/GIP/glucagon triple agonist for obesity and type 2 diabetes. It originated with United Biotechnology and was licensed outside China by Novo Nordisk in 2025. It uses the same three-receptor strategy as retatrutide.
In a Phase 2 trial in Chinese adults, UBT251 produced up to 19.7% weight loss at 24 weeks. Longer, larger global trials are needed to confirm efficacy and compare it with approved drugs.
No, but they share a mechanism. Both are GLP-1/GIP/glucagon triple agonists. Retatrutide (Eli Lilly) is further along in Phase 3; UBT251 (Novo/United Biotechnology) is earlier in global development.
No. UBT251 is investigational and not available by prescription. Global data is expected around 2027. Any retail "UBT251" is unverified and unsafe.
Yes. Shotlee tracks any GLP-1-class protocol — doses, weight, and side effects — including investigational triple agonists like retatrutide and UBT251 if you are in a trial.
Track Any GLP-1 Protocol in Shotlee
Free dose logs, weight trends, and side-effect tracking — for approved and investigational incretin drugs alike.